to torrestaurants in italy. live from cnn center, this is cnn newsroom with ken brunhuber. there s a growing sense of urgency among members of congress ahead of monday s second hearing on the january 6 insurrection. they say their investigation paints a tdamning portrait of former president trump. trump and his supporters have been pushing back hard against the narrative. we get more from jessica sh th needer in washington. reporter: they set the stage tor for what s to come. some republicans are working to discredit the findings, while the former president is responding to this. the president responded with this sentiment. maybe our supporters have the right idea. mike pence, quote, deserves it. reporter: today trump responding. i never said or even thought of saying hang mike pence . this is either a made-up story from someone looking to be a star or fake news. we want trump! reporter: and his months-long efforts to discredit the election, leading to what t
Explore the groundbreaking shift in frontline treatment for endometrial cancer, driven by recent data from trials like RUBY and GY018, highlighting the significant impact of checkpoint inhibitors in patients with mismatch repair deficiency.
Exploring treatment options for patients with recurrent mismatch repair deficient endometrial cancer, including the choice between single-agent checkpoint inhibitors and chemo-immunotherapy combinations, with insights from GARNET and KEYNOTE-158 studies.
Emma L. Barber, MD, discusses how key data from the phase 3 KEYNOTE-775 study improved the identification of patient populations within endometrial cancer that benefit from second-line immunotherapy.